Abstract
ADVERSE EVENTS IN PATIENTS WITH LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS <25 OR <15 MG/DL ON AT LEAST TWO CONSECUTIVE VISITS IN FOURTEEN RANDOMIZED, CONTROLLED, CLINICAL TRIALS OF ALIROCUMAB
Journal of the American College of Cardiology, Vol.65(10), pp.A1350-A1350
03/17/2015
DOI: 10.1016/S0735-1097(15)61350-X
Abstract
Consequences of very low LDL-C levels are not well understood. [...]AE rates were examined in patients (pts) who achieved 2 consecutive calculated LDL-C <25 or <15 mg/dL on alirocumab (ALI).
Details
- Title: Subtitle
- ADVERSE EVENTS IN PATIENTS WITH LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS <25 OR <15 MG/DL ON AT LEAST TWO CONSECUTIVE VISITS IN FOURTEEN RANDOMIZED, CONTROLLED, CLINICAL TRIALS OF ALIROCUMAB
- Creators
- Jennifer RobinsonMichel Farnier - Regeneron (United States)Umesh Chaudhari - Regeneron (United States)Bill Sasiela - Regeneron (United States)Christelle Lorenzato - Regeneron (United States)Kathryn Miller - Regeneron (United States)John Kastelein
- Resource Type
- Abstract
- Publication Details
- Journal of the American College of Cardiology, Vol.65(10), pp.A1350-A1350
- DOI
- 10.1016/S0735-1097(15)61350-X
- ISSN
- 0735-1097
- eISSN
- 1558-3597
- Publisher
- Elsevier Limited
- Language
- English
- Date published
- 03/17/2015
- Academic Unit
- Epidemiology; Fraternal Order of Eagles Diabetes Research Center
- Record Identifier
- 9984364372502771
Metrics
18 Record Views